Autres langues AstraZeneca PLC NYSE

Actions

AZN

US0463531089

Produits pharmaceutiques

Marché Fermé - NYSE 22:00:02 05/10/2026			Pré-ouverture 14:50:02
156,53 ^USD	-0,24 %		158,10	+1,01 %

12:58	Large hausse à la Bourse de Stockholm, l’indice OMXS30 progresse de 1,2 %	FW
12:44	Les actions britanniques progressent, portées par le repli du pétrole et la détente des rendements des gilts	RE

Autres langues

14:44	Stocks Are Testing the Bond Market
12:44	UK shares rise as softer oil, easing gilt yields lift sentiment
11:04	AstraZeneca : Alexion to showcase Phase III data in hypophosphatasia and hypoparathyroidism at ASBMR 2026 Annual Meeting
09:45	Los índices bursátiles europeos suben impulsados por el sector sanitario -- Market Talk
08:45	Morning Meeting: Las bolsas siguen subiendo, como el coste de la vida
08:44	AstraZeneca Invests Over $1bn in Massachusetts
08:32	Morning Meeting: Aktien steigen weiter, genau wie die Lebenshaltungskosten
08:10	Stocks, Like the Cost of Living, Keep Going Up
07:02	BofA Forecasts 'In-line' Q3, Unchanged FY26 Outlook for AstraZeneca Amid Oncology Momentum
06:48	UK Stocks-Factors to watch on October 6
05:27	AstraZeneca Launches Research, Development Center in US
05/10	AztraZeneca opens new global strategic R&D centre in Massachusetts
05/10	AstraZeneca to Invest Over $1 Billion in Massachusetts
05/10	AstraZeneca to Invest Over $1 Billion in Massachusetts
05/10	AstraZeneca to invest over $1 billion in Massachusetts, boost workforce
05/10	AstraZeneca opens new Massachusetts R&D center as part of $1 billion investment
05/10	AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
05/10	Astrazeneca Announces the Opening of Its Newest Global Strategic Research and Development (R&D) Center, in Kendall Square, Cambridge, Massachusetts
05/10	Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
05/10	AstraZeneca completes USD2 billion Summit investment
05/10	Summit Therapeutics Secures $2 Billion Investment From AstraZeneca
05/10	AstraZeneca Finalizes $2 Billion Investment in Summit Therapeutics
02/10	AbbVie joins US government pilot to test drug discount rebates
02/10	Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
02/10	AstraZeneca PLC, Daiichi Sankyo And Summit Therapeutics Inc. Announce Clinical Collaboration To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types